| 2.91 -0.25 (-7.91%) | 01-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.26 | 1-year : | 4.85 |
| Resists | First : | 3.65 | Second : | 4.15 |
| Pivot price | 3.34 |
|||
| Supports | First : | 2.84 | Second : | 2.36 |
| MAs | MA(5) : | 3 |
MA(20) : | 3.38 |
| MA(100) : | 3.38  |
MA(250) : | 3.22 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 14.1 |
D(3) : | 11.3 |
| RSI | RSI(14): 39 |
|||
| 52-week | High : | 6.32 | Low : | 2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ABSI ] has closed above bottom band by 18.0%. Bollinger Bands are 15% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.13 - 3.15 | 3.15 - 3.17 |
| Low: | 2.86 - 2.88 | 2.88 - 2.9 |
| Close: | 2.88 - 2.91 | 2.91 - 2.94 |
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Wed, 14 Jan 2026
Analysts Cut Absci (ABSI) Target, Spotlight New Alopecia Therapy in Early Trials - Yahoo Finance
Thu, 08 Jan 2026
Absci (NASDAQ:ABSI) Shares Down 9.1% - Here's What Happened - MarketBeat
Thu, 08 Jan 2026
Morgan Stanley downgrades Absci stock on TL1A setback and higher risk profile - Investing.com
Tue, 30 Dec 2025
Absci Corporation (ABSI) Announces First Participants Dosed In Phase 1/2a HEADLINE Trial - Yahoo Finance
Sat, 27 Dec 2025
Absci Corporation (ABSI) Draws Full Buy Consensus With 150% Upside Potential - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 150 (M) |
| Held by Insiders | 1.3273e+008 (%) |
| Held by Institutions | 9.2 (%) |
| Shares Short | 32,380 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.055e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -7 % |
| Return on Assets (ttm) | 977.2 % |
| Return on Equity (ttm) | -30.7 % |
| Qtrly Rev. Growth | 2.81e+006 % |
| Gross Profit (p.s.) | -36.53 |
| Sales Per Share | -26.15 |
| EBITDA (p.s.) | -3.29718e+007 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -81 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.12 |
| Price to Cash Flow | 4.42 |
| Dividend | 0 |
| Forward Dividend | 3.555e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|